# Alector, Inc.: financial statements, quarterly

ALEC · Nasdaq · CIK 1653087 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alec.md) · [Financials](/companies/alec/financials.md) · [Filings](/companies/alec/filings.md) · [Insiders](/companies/alec/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alec/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9.1](/filings/0000950170-24-122328.md) | [15.2 d](/filings/0000950170-25-027758.md) | [15.9](/filings/0000950170-25-066987.md) | [15.1](/filings/0000950170-25-105050.md) | [15.3](/filings/0001193125-25-269592.md) | [54.2 d](/filings/0001193125-26-071593.md) | [3.7](/filings/0001193125-26-211981.md) | [7.9](/filings/0001193125-26-338052.md) | [3.3](/filings/0001193125-25-269592.md) | [6.2 d](/filings/0001193125-26-071593.md) | [1.0](/filings/0001193125-26-211981.md) | [3.3](/filings/0001193125-26-338052.md) |
| Research and development | $m | [46.3](/filings/0000950170-24-122328.md) | [47.7 d](/filings/0000950170-25-027758.md) | [45.2](/filings/0000950170-25-066987.md) | [46.3](/filings/0000950170-25-105050.md) | [48.0](/filings/0001193125-25-269592.md) | [46.5 d](/filings/0001193125-26-071593.md) | [33.6](/filings/0001193125-26-211981.md) | [27.6](/filings/0001193125-26-338052.md) | [29.4](/filings/0001193125-25-269592.md) | [32.5 d](/filings/0001193125-26-071593.md) | [17.9](/filings/0001193125-26-211981.md) | [19.5](/filings/0001193125-26-338052.md) |
| Operating income | $m | [(50.6)](/filings/0000950170-24-122328.md) | [(47.5) d](/filings/0000950170-25-027758.md) | [(43.7)](/filings/0000950170-25-066987.md) | [(45.6)](/filings/0000950170-25-105050.md) | [(48.4)](/filings/0001193125-25-269592.md) | [(7.2) d](/filings/0001193125-26-071593.md) | [(44.7)](/filings/0001193125-26-211981.md) | [(34.1)](/filings/0001193125-26-338052.md) | [(37.6)](/filings/0001193125-25-269592.md) | [(39.6) d](/filings/0001193125-26-071593.md) | [(24.9)](/filings/0001193125-26-211981.md) | [(24.4)](/filings/0001193125-26-338052.md) |
| Income tax | $m | [1.3](/filings/0000950170-24-122328.md) | [1.7 d](/filings/0000950170-25-027758.md) | [0.0](/filings/0000950170-25-066987.md) | [0.1](/filings/0000950170-25-105050.md) | [0.0](/filings/0001193125-25-269592.md) | [0.0 d](/filings/0001193125-26-071593.md) | [0.0](/filings/0001193125-26-211981.md) | [0.0](/filings/0001193125-26-338052.md) | [0.0](/filings/0001193125-25-269592.md) | [0.2 d](/filings/0001193125-26-071593.md) | [0.0](/filings/0001193125-26-211981.md) | [0.1](/filings/0001193125-26-338052.md) |
| Net income | $m | [(44.5)](/filings/0000950170-24-122328.md) | [(41.4) d](/filings/0000950170-25-027758.md) | [(36.1)](/filings/0001193125-25-269592.md) | [(38.7)](/filings/0001193125-25-269592.md) | [(42.2)](/filings/0001193125-25-269592.md) | [(2.1) d](/filings/0001193125-26-071593.md) | [(40.5)](/filings/0001193125-26-338052.md) | [(30.5)](/filings/0001193125-26-338052.md) | [(34.7)](/filings/0001193125-25-269592.md) | [(37.3) d](/filings/0001193125-26-071593.md) | [(22.9)](/filings/0001193125-26-338052.md) | [(23.0)](/filings/0001193125-26-338052.md) |
| Diluted EPS | $ per share | [(0.53)](/filings/0000950170-24-122328.md) | not reported | [(0.38)](/filings/0000950170-25-066987.md) | [(0.40)](/filings/0000950170-25-105050.md) | [(0.43)](/filings/0001193125-25-269592.md) | not reported | [(0.41)](/filings/0001193125-26-211981.md) | [(0.30)](/filings/0001193125-26-338052.md) | [(0.34)](/filings/0001193125-25-269592.md) | not reported | [(0.21)](/filings/0001193125-26-211981.md) | [(0.21)](/filings/0001193125-26-338052.md) |
| Basic EPS | $ per share | [(0.53)](/filings/0000950170-24-122328.md) | not reported | [(0.38)](/filings/0000950170-25-066987.md) | [(0.40)](/filings/0000950170-25-105050.md) | [(0.43)](/filings/0001193125-25-269592.md) | not reported | [(0.41)](/filings/0001193125-26-211981.md) | [(0.30)](/filings/0001193125-26-338052.md) | [(0.34)](/filings/0001193125-25-269592.md) | not reported | [(0.21)](/filings/0001193125-26-211981.md) | [(0.21)](/filings/0001193125-26-338052.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [102](/filings/0000950170-24-122328.md) | [74.6](/filings/0000950170-25-027758.md) | [72.6](/filings/0000950170-25-066987.md) | [47.5](/filings/0000950170-25-105050.md) | [37.2](/filings/0001193125-25-269592.md) | [33.0](/filings/0001193125-26-071593.md) | [38.0](/filings/0001193125-26-211981.md) | [44.8](/filings/0001193125-26-338052.md) | [76.5](/filings/0001193125-25-269592.md) | [65.8](/filings/0001193125-26-338052.md) | [77.0](/filings/0001193125-26-211981.md) | [59.9](/filings/0001193125-26-338052.md) |
| Current assets | $m | [613](/filings/0000950170-23-060270.md) | [566](/filings/0000950170-25-027758.md) | [581](/filings/0000950170-24-055682.md) | [520](/filings/0000950170-24-092814.md) | [469](/filings/0000950170-24-122328.md) | [425](/filings/0001193125-26-071593.md) | [367](/filings/0000950170-25-066987.md) | [319](/filings/0000950170-25-105050.md) | [300](/filings/0001193125-25-269592.md) | [266](/filings/0001193125-26-338052.md) | [215](/filings/0001193125-26-211981.md) | [180](/filings/0001193125-26-338052.md) |
| Total assets | $m | [672](/filings/0000950170-23-060270.md) | [622](/filings/0000950170-25-027758.md) | [635](/filings/0000950170-24-055682.md) | [571](/filings/0000950170-24-092814.md) | [516](/filings/0000950170-24-122328.md) | [468](/filings/0001193125-26-071593.md) | [408](/filings/0000950170-25-066987.md) | [356](/filings/0000950170-25-105050.md) | [335](/filings/0001193125-25-269592.md) | [293](/filings/0001193125-26-338052.md) | [240](/filings/0001193125-26-211981.md) | [203](/filings/0001193125-26-338052.md) |
| Current liabilities | $m | [155](/filings/0000950170-23-060270.md) | [178](/filings/0000950170-25-027758.md) | [165](/filings/0000950170-24-055682.md) | [148](/filings/0000950170-24-092814.md) | [143](/filings/0000950170-24-122328.md) | [125](/filings/0001193125-26-071593.md) | [110](/filings/0000950170-25-066987.md) | [84.4](/filings/0000950170-25-105050.md) | [80.0](/filings/0001193125-25-269592.md) | [69.5](/filings/0001193125-26-338052.md) | [41.0](/filings/0001193125-26-211981.md) | [34.2](/filings/0001193125-26-338052.md) |
| Total liabilities | $m | [510](/filings/0000950170-23-060270.md) | [488](/filings/0000950170-25-027758.md) | [457](/filings/0000950170-24-055682.md) | [420](/filings/0000950170-24-092814.md) | [397](/filings/0000950170-24-122328.md) | [342](/filings/0001193125-26-071593.md) | [314](/filings/0000950170-25-066987.md) | [285](/filings/0000950170-25-105050.md) | [278](/filings/0001193125-25-269592.md) | [263](/filings/0001193125-26-338052.md) | [230](/filings/0001193125-26-211981.md) | [213](/filings/0001193125-26-338052.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0000950170-25-027758.md) | not reported | not reported | not reported | [9.4](/filings/0001193125-26-071593.md) | [9.5](/filings/0000950170-25-066987.md) | [9.5](/filings/0000950170-25-105050.md) | [9.6](/filings/0001193125-25-269592.md) | [9.3](/filings/0001193125-26-338052.md) | [8.3](/filings/0001193125-26-211981.md) | [0.0](/filings/0001193125-26-338052.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.4](/filings/0001193125-26-338052.md) | not reported | [9.8](/filings/0001193125-26-338052.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-071593.md) | not reported | not reported | not reported | [0.4](/filings/0001193125-26-211981.md) | [1.5](/filings/0001193125-26-211981.md) | not reported |
| Shareholders' equity | $m | [163](/filings/0000950170-24-122328.md) | [134](/filings/0001193125-26-071593.md) | [179](/filings/0001193125-25-269592.md) | [151](/filings/0001193125-25-269592.md) | [119](/filings/0001193125-25-269592.md) | [127](/filings/0001193125-26-338052.md) | [94.6](/filings/0001193125-26-338052.md) | [71.2](/filings/0001193125-26-338052.md) | [57.7](/filings/0001193125-25-269592.md) | [30.6](/filings/0001193125-26-338052.md) | [10.4](/filings/0001193125-26-338052.md) | [(10.0)](/filings/0001193125-26-338052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(46.5) d](/filings/0000950170-24-122328.md) | [(46.1) d](/filings/0000950170-25-027758.md) | [(61.3)](/filings/0000950170-25-066987.md) | [(62.8) d](/filings/0000950170-25-105050.md) | [(50.7) d](/filings/0001193125-25-269592.md) | [(55.0) d](/filings/0001193125-26-071593.md) | [(60.8)](/filings/0001193125-26-211981.md) | [(49.0) d](/filings/0001193125-26-338052.md) | [(32.5) d](/filings/0001193125-25-269592.md) | [(41.7) d](/filings/0001193125-26-071593.md) | [(49.8)](/filings/0001193125-26-211981.md) | [(34.2) d](/filings/0001193125-26-338052.md) |
| Capital expenditure | $m | [(0.1) d](/filings/0000950170-24-122328.md) | [0.2 d](/filings/0000950170-25-027758.md) | [0.5](/filings/0000950170-25-066987.md) | [0.3 d](/filings/0000950170-25-105050.md) | [0.2 d](/filings/0001193125-25-269592.md) | [0.2 d](/filings/0001193125-26-071593.md) | [0.0](/filings/0001193125-26-211981.md) | [0.0 d](/filings/0001193125-26-338052.md) | [0.0 d](/filings/0001193125-25-269592.md) | [0.0 d](/filings/0001193125-26-071593.md) | [0.1](/filings/0001193125-26-211981.md) | [0.0 d](/filings/0001193125-26-338052.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [82.6](/filings/0000950170-23-060270.md) | [83.1](/filings/0000950170-24-055682.md) | [83.6](/filings/0000950170-24-092814.md) | [83.9](/filings/0000950170-24-122328.md) | [93.8](/filings/0000950170-25-066987.md) | [96.7](/filings/0000950170-25-105050.md) | [97.5](/filings/0001193125-25-269592.md) | [99.4](/filings/0001193125-26-211981.md) | [100](/filings/0001193125-26-338052.md) | [103](/filings/0001193125-25-269592.md) | [111](/filings/0001193125-26-211981.md) | [111](/filings/0001193125-26-338052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 111,656,919 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.